Kyowa Hakko Kirin Pledges To Become Japan’s Top Biotech-based Pharma – Bio Japan
This article was originally published in PharmAsia News
Executive Summary
YOKOHAMA, Japan - Yuzuru Matsuda, president and CEO of Kyowa Hakko Kirin Co., said his company aimed to become "the top-class global biotechnology-based pharma that does research and development in the area of life sciences out of Japan, continuously making innovative contributions with antibody drugs." Matsuda spoke to an audience at Bio Japan in Yokohama Oct. 17